SGLT2 inhibitors in type 2 diabetes, a systematic review and meta-analysis of cardiovascular outcome trials balancing their benefits against their risks

被引：0

作者：

Marilly, E. ^{[1
]}

Cottin, J. ^{[1
]}

Cabrera, N. ^{[2
]}

Cornu, C. ^{[3
]}

Boussageon, R. ^{[4
]}

Moulin, P. ^{[5
]}

Lega, J. C. ^{[6
,7
]}

Gueyffier, F. ^{[2
]}

Cucherat, M. ^{[2
]}

Grenet, G. ^{[1
]}

机构：

[1] Hosp Civils Lyon, Serv Hosp Univ Pharmacotoxicol, Pole Sante Publ, Lyon, France

[2] Univ Lyon, Univ Lyon 1, CNRS, Lab Biometrie & Biol Evolut Umr 5558, Lyon, France

[3] Hosp Civils Lyon, CIC1407 Inserm, Lyon, France

[4] Univ Lyon, Dept Med Gen, Lyon, France

[5] Univ Lyon 1, Inserm UMR 1060 Carmen Hosp Civils Lyon, Federat Endocrinol Malad Metab Diabete & Nutr, Lyon, France

[6] Hosp Civils Lyon Vasc, Serv Med Interne, Lyon, France

[7] Hosp Civils Lyon Vasc, Hop Lyon Sud, Lyon, France

来源：

关键词：

type; 2; diabetes; SGLT2; inhibitors; Gliflozin; cardiovascular disease; benefit-risk balance; meta-analysis;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PS-142

引用

页码：168 / 168

页数：1